Aquila are attending the 14th Annual Biomarkers Congress 2019 21-22nd February.
If you would like to find out more about our Immunology, Immuno-Oncology or Specialist Histology services, please connect with Louise Welch.
Over 350 attendees representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions working in the biomarker space across multiple therapeutic areas, such as immuno-oncology, neuroscience and cardiology.
We will also be presenting our poster titled “Biomarker Detection Using a Mixed Multiplex Approach”, an abstract of this poster can be found below:
Authors: Mike Millar, Louise Welch, Dawn Lyster, Mariana Beltran, Sevi Giakoumelou, Steve Anderton
The immuno-oncology (IO) drug discovery pipeline research requires a multi-staged approach – pre-clinical in vitro assays, in vivo studies and histological analysis of tumour tissue. We demonstrate the power of utilising a specialist histological approach during the pre-clinical in vitro stage. Combining functional in vitro assay readouts with detection in formalin fixed paraffin embedded (FFPE) tissue can inform the expression of the target in different cancers. Simultaneously imaging multiple IO markers on a section provides morphological, pathological and spatial information of the juxtaposition of different immune cell types, which are quantifiable using image analysis techniques.
For conference updates from Aquila, connect with us on LinkedIn and Twitter.
We hope to see you there!